Create a free PharmData login to receive notifications. An active Starter or Pro subscription enables your pharmacy team to record assessments and follow-up actions.
Tredaptive modified-release tablets - withdrawn throughout the European Union
(Merck Sharp & Dohme Ltd) Study showed failure to reduce major vascular events and increase in non-fatal serious adverse events – class 2 action within 48 hours. (EL (13)A/02)
Source: Medicines and Healthcare products Regulatory Agency (MHRA). Read the full notice, including its required actions and deadlines, before recording your response.